Clovis raising $250M to fund commercialization work; FDA accepts Adaptimmune IND;

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Novartis says Entresto will be priced at $12.50 a day. More | Follow @JohnCFierce

@DamianFierce: Entresto, described by $NVS CEO Joe Jimenez as a "multi-blockbuster," is now approved to treat heart failure. More | Follow @DamianFierce

> Boulder, CO-based Clovis Oncology ($CLVS) is raising $250 million through the sale of shares, primarily to set up commercialization programs for rociletinib and rucaparib. Release

> Adaptimmune Therapeutics' ($ADAP) IND for genetically modified T-cells expressing enhanced T-cell receptors (TCRs) specific for MAGE A1 has been accepted by the FDA. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Mindray down on the acquisition of remainder of Chinese orthopedics company for $72.6M. Article | Follow @FierceMedDev

@EmilyWFierce: JAMA: Mammography does not reduce breast cancer deaths, could result in overdiagnosis. Story | Follow @EmilyWFierce

> Theranos signs its first health insurer in a deal with Capital BlueCross. More

> Device makers to offer stronger guarantees on products if they fail to perform. Story

Pharma News

@FiercePharma: Got an idea for an FDA drug study? Send an email. Editor's corner | Follow @FiercePharma

@EricPFierce: Our Twitter chat is less than an hour off. Don't miss the discussion on #sustainedrelease with BASF expert Thorsten Cech. @BASF_Pharma | Follow @EricPFierce

@CarlyHFierce: Roche's MS hopeful will amp up payer pricing pressure, analyst says. Article | Follow @CarlyHFierce

> Sunshine Act payment data leaves out newly influential prescribers. More

> Sun's remolding of Ranbaxy continues as another top exec is reportedly out. News

Biotech Research News

> UC San Diego accuses USC of conspiring to grab Alzheimer's research, funding. Report

> Computer scientists warn about the coming tsunami of genomics data. News

> Falsely accused 'Rambo' protein actually guards against heart failure. More

> UCSD researchers point to promising new drug target for glioblastoma. Story

> Researchers launch PhI study to test new approach to T cell immunotherapy. Article

Diagnostics News

> Theranos nabs FDA clearance for finger-stick herpes test. More

> BG Medicine gets FDA blessing for automated chronic heart failure test. Report

> Natera bags $180M in IPO to ramp up R&D. News

> Epic Sciences and LabCorp expand global reach with Asia clinical trials deal. Story

> Quest and Quintiles rev up new lab testing JV. Article

Pharma Marketing News

> Roche's MS hopeful will amp up payer pricing pressure, analyst says. News

> Bydureon, Invokana, Xarelto brand teams shelled out most to doctors in 2014. Article

> Merck, Samsung rack up data on Humira biosim, setting stage for approval apps. More

> Pfizer's Viagra first ED drug available in single-dose packets. Story

> Early Avycaz sales could signal bigger payoff for superbug-fighting antibiotics. Report

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.